首页 > 最新文献

Current Problems in Cancer最新文献

英文 中文
Contribution of BARD1 gene to male breast cancer- report of a family with different types of cancer BARD1基因在男性乳腺癌中的作用——一个不同类型癌症家族的报告
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2025-10-03 DOI: 10.1016/j.currproblcancer.2025.101254
Akram Sarmadi , Shaghayegh Haghjooy Javanmard , Mehrdad Zeinalian , Majid Hosseinzadeh , Zahra Nouri , Mohammad Amin Tabatabaiefar

Background

Breast cancer (BC) arises from a combination of genetic and environmental factors, continues to be the leading cause of cancer-related mortality among women. Although male BC accounts for <1 % of all BC cases, its incidence seems to be increasing. Germline pathogenic variants in cancer susceptibility genes underlie about 30 % of male BC patients. This study aimed to identify the genetic cause of BC in a man to facilitate his clinical management and enable genetic counseling and preventive screening for his at-risk relatives.

Methods

We conducted a clinical examination and molecular genetic testing on a man with BC having a family history of several malignancies. BRCA sequencing panel followed by exome sequencing (ES) were performed and bioinformatics tools were used to evaluate the variants’ pathogenicity. ACMG guidelines was used for the variant interpretation and Sanger sequencing and co-segregation analysis were performed for its confirmation.

Results

According to ES findings, a novel heterozygous variant (c.1802T>C) was detected in the BARD1 gene, fulfilling the pathogenic criteria. The proband’s brother, suffering from colorectal cancer, was also found to harbor this variant, suggesting its role in the familial clustering of both breast and colorectal cancer.

Conclusion

We successfully identified a novel BARD1 pathogenic variant in an Iranian man suffering from BC. Identification of disease-causing variant in some cancer, especially male BC can be useful in genetic counseling, early diagnosis and implementing preventive measures. We also recommend cancer genetic counseling for the healthy at-risk family members, with a focus on different hereditary cancer syndromes.
乳腺癌(BC)由遗传和环境因素共同引起,一直是女性癌症相关死亡的主要原因。虽然男性BC占所有BC病例的1%,但其发病率似乎在增加。癌症易感基因的种系致病性变异是约30%男性BC患者的基础。本研究旨在确定男性BC的遗传原因,以促进其临床管理,并为其高危亲属提供遗传咨询和预防性筛查。方法对1例有多种恶性肿瘤家族史的男性BC患者进行临床检查和分子基因检测。进行BRCA测序面板和外显子组测序(ES),并使用生物信息学工具评估变异的致病性。使用ACMG指南进行变异解释,并进行Sanger测序和共分离分析以确认其结果。结果在BARD1基因中检测到一个新的杂合变异(C . 1802t>;C),符合致病标准。该先证者患有结直肠癌的兄弟也被发现携带这种变异,这表明它在乳腺癌和结直肠癌的家族聚集性中发挥了作用。结论:我们成功鉴定出一种新的BARD1致病性变异。识别某些癌症的致病变异,特别是男性BC,可用于遗传咨询、早期诊断和实施预防措施。我们还建议癌症遗传咨询健康的高危家庭成员,重点是不同的遗传性癌症综合征。
{"title":"Contribution of BARD1 gene to male breast cancer- report of a family with different types of cancer","authors":"Akram Sarmadi ,&nbsp;Shaghayegh Haghjooy Javanmard ,&nbsp;Mehrdad Zeinalian ,&nbsp;Majid Hosseinzadeh ,&nbsp;Zahra Nouri ,&nbsp;Mohammad Amin Tabatabaiefar","doi":"10.1016/j.currproblcancer.2025.101254","DOIUrl":"10.1016/j.currproblcancer.2025.101254","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer (BC) arises from a combination of genetic and environmental factors, continues to be the leading cause of cancer-related mortality among women. Although male BC accounts for &lt;1 % of all BC cases, its incidence seems to be increasing. Germline pathogenic variants in cancer susceptibility genes underlie about 30 % of male BC patients. This study aimed to identify the genetic cause of BC in a man to facilitate his clinical management and enable genetic counseling and preventive screening for his at-risk relatives.</div></div><div><h3>Methods</h3><div>We conducted a clinical examination and molecular genetic testing on a man with BC having a family history of several malignancies. BRCA sequencing panel followed by exome sequencing (ES) were performed and bioinformatics tools were used to evaluate the variants’ pathogenicity. ACMG guidelines was used for the variant interpretation and Sanger sequencing and co-segregation analysis were performed for its confirmation.</div></div><div><h3>Results</h3><div>According to ES findings, a novel heterozygous variant (c.1802T&gt;<em>C</em>) was detected in the <em>BARD1</em> gene, fulfilling the pathogenic criteria. The proband’s brother, suffering from colorectal cancer, was also found to harbor this variant, suggesting its role in the familial clustering of both breast and colorectal cancer.</div></div><div><h3>Conclusion</h3><div>We successfully identified a novel <em>BARD1</em> pathogenic variant in an Iranian man suffering from BC. Identification of disease-causing variant in some cancer, especially male BC can be useful in genetic counseling, early diagnosis and implementing preventive measures. We also recommend cancer genetic counseling for the healthy at-risk family members, with a focus on different hereditary cancer syndromes.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"59 ","pages":"Article 101254"},"PeriodicalIF":2.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145221791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hormone replacement therapy in endometrial cancer survivors: A retrospective cohort study on recurrence, survival, and quality of life. 子宫内膜癌幸存者的激素替代疗法:关于复发、生存和生活质量的回顾性队列研究。
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2025-10-01 Epub Date: 2025-08-07 DOI: 10.1016/j.currproblcancer.2025.101239
Jiali Xing, Qi Liu, Li Qiao

Background: Endometrial cancer is the most common gynecologic malignancy in developed countries, often affecting postmenopausal women but also seen in younger patients. Standard treatment includes hysterectomy with bilateral salpingo-oophorectomy, which may lead to menopausal symptoms, especially in premenopausal women. The use of hormone replacement therapy (HRT) in survivors remains controversial due to concerns about stimulating cancer cells. This study aims to evaluate the impact of postoperative HRT on cancer recurrence, survival outcomes, and quality of life in endometrial cancer survivors.

Methods: This retrospective cohort study analyzed 176 women -between August 2024 and May 2025- with histologically confirmed endometrial adenocarcinoma. Participants were categorized into HRT users (n = 91) and non-users (n = 85) with a median age of 58 and 62 years respectively. Demographic, clinical, and treatment data were compared. Survival analyses were conducted using Kaplan-Meier and Cox regression models. Quality of life was assessed using the MENQOL questionnaire.

Results: HRT use was associated with lower recurrence (HR=0.379, p = 0.002) and death hazard (HR=0.248, p = 0.039) rates. Mean recurrence-free survival was longer in the HRT group (53.14 vs 46.28 months, p < 0.001). Improvement in menopausal symptom scores was significantly higher in HRT users (MD= -2.03) compared to the control group (MD= -0.89). No significant increase in adverse cardiovascular or thromboembolic events was observed.

Conclusion: Postoperative HRT appears safe and beneficial for selected endometrial cancer survivors, offering improved recurrence-free survival and better menopausal symptom control without increasing serious adverse events. Individualized assessment remains crucial, and further prospective trials are needed to confirm these findings.

背景:子宫内膜癌是发达国家最常见的妇科恶性肿瘤,常影响绝经后妇女,但也见于年轻患者。标准治疗包括子宫切除术和双侧输卵管卵巢切除术,这可能导致更年期症状,特别是绝经前妇女。由于担心刺激癌细胞,在幸存者中使用激素替代疗法(HRT)仍然存在争议。本研究旨在评估子宫内膜癌术后HRT对癌症复发、生存结果和生活质量的影响。方法:这项回顾性队列研究分析了176名组织学证实为子宫内膜腺癌的女性,时间为2024年8月至2025年5月。参与者被分为HRT使用者(n = 91)和非使用者(n = 85),中位年龄分别为58岁和62岁。比较人口学、临床和治疗数据。生存率分析采用Kaplan-Meier和Cox回归模型。使用MENQOL问卷评估生活质量。结果:HRT使用与较低的复发率(HR=0.379, p = 0.002)和死亡风险(HR=0.248, p = 0.039)相关。HRT组的平均无复发生存期更长(53.14个月vs 46.28个月,p < 0.001)。与对照组(MD= -0.89)相比,HRT使用者(MD= -2.03)绝经期症状评分的改善明显更高。没有观察到不良心血管或血栓栓塞事件的显著增加。结论:对于选定的子宫内膜癌幸存者,术后HRT似乎是安全有益的,可以提高无复发生存率,更好地控制更年期症状,而不会增加严重不良事件。个性化评估仍然至关重要,需要进一步的前瞻性试验来证实这些发现。
{"title":"Hormone replacement therapy in endometrial cancer survivors: A retrospective cohort study on recurrence, survival, and quality of life.","authors":"Jiali Xing, Qi Liu, Li Qiao","doi":"10.1016/j.currproblcancer.2025.101239","DOIUrl":"10.1016/j.currproblcancer.2025.101239","url":null,"abstract":"<p><strong>Background: </strong>Endometrial cancer is the most common gynecologic malignancy in developed countries, often affecting postmenopausal women but also seen in younger patients. Standard treatment includes hysterectomy with bilateral salpingo-oophorectomy, which may lead to menopausal symptoms, especially in premenopausal women. The use of hormone replacement therapy (HRT) in survivors remains controversial due to concerns about stimulating cancer cells. This study aims to evaluate the impact of postoperative HRT on cancer recurrence, survival outcomes, and quality of life in endometrial cancer survivors.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed 176 women -between August 2024 and May 2025- with histologically confirmed endometrial adenocarcinoma. Participants were categorized into HRT users (n = 91) and non-users (n = 85) with a median age of 58 and 62 years respectively. Demographic, clinical, and treatment data were compared. Survival analyses were conducted using Kaplan-Meier and Cox regression models. Quality of life was assessed using the MENQOL questionnaire.</p><p><strong>Results: </strong>HRT use was associated with lower recurrence (HR=0.379, p = 0.002) and death hazard (HR=0.248, p = 0.039) rates. Mean recurrence-free survival was longer in the HRT group (53.14 vs 46.28 months, p < 0.001). Improvement in menopausal symptom scores was significantly higher in HRT users (MD= -2.03) compared to the control group (MD= -0.89). No significant increase in adverse cardiovascular or thromboembolic events was observed.</p><p><strong>Conclusion: </strong>Postoperative HRT appears safe and beneficial for selected endometrial cancer survivors, offering improved recurrence-free survival and better menopausal symptom control without increasing serious adverse events. Individualized assessment remains crucial, and further prospective trials are needed to confirm these findings.</p>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"58 ","pages":"101239"},"PeriodicalIF":2.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Angiogenesis biomarkers in prostate cancer: Unlocking new avenues for prognosis and diagnosis 前列腺癌血管生成生物标志物:为预后和诊断开辟新的途径。
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2025-09-27 DOI: 10.1016/j.currproblcancer.2025.101253
Büşra Ecer , Abdullah Sivrikaya , Gökhan Ecer , Serdar Göktaş , Mehmet Yıldız , Mehmet Balasar , Ali Ünlü

Objective

To evaluate the levels of angiogenesis-related biomarkers, including Thrombospondin-1 (TSP1), Endostatin, Osteopontin, and Tumstatin, in prostate cancer patients and their relationship with tumor spread and clinical parameters.

Methods

This prospective study included 92 participants divided into three groups: 33 prostate cancer patients, 29 patients with benign prostatic hyperplasia (BPH), and 30 healthy controls. Biomarker levels were analyzed and compared among the groups.

Results

Osteopontin levels were significantly higher in the prostate cancer group (108.5 ng/mL) compared to the BPH (66.02 ng/mL) and control groups (56.5 ng/mL). TSP1 levels were lower in prostate cancer group (16.3 ng/mL) than in the BPH (25.3 ng/mL) and control groups (21.5 ng/mL). Similarly, Endostatin levels were reduced in the prostate cancer group (146.3 ng/mL) compared to the BPH (163.3 ng/mL) and control groups (166.2 ng/mL). No significant differences in Tumstatin levels were observed among the groups.

Conclusions

Elevated Osteopontin levels correlate with higher Gleason scores and metastatic potential, while lower TSP1 and Endostatin levels are associated with advanced tumor progression. These biomarkers may serve as indicators of prognosis in prostate cancer, though larger studies are required for validation.
目的:探讨前列腺癌患者血管生成相关标志物血栓反应蛋白-1 (TSP1)、内皮抑素(Endostatin)、骨桥蛋白(Osteopontin)和Tumstatin的水平及其与肿瘤扩散和临床参数的关系。方法:这项前瞻性研究包括92名参与者,分为三组:33名前列腺癌患者,29名良性前列腺增生(BPH)患者和30名健康对照。分析并比较各组生物标志物水平。结果:前列腺癌组骨桥蛋白水平(108.5 ng/mL)明显高于前列腺增生组(66.02 ng/mL)和对照组(56.5 ng/mL)。前列腺癌组TSP1水平(16.3 ng/mL)低于BPH组(25.3 ng/mL)和对照组(21.5 ng/mL)。同样,前列腺癌组内皮抑素水平(146.3 ng/mL)低于BPH组(163.3 ng/mL)和对照组(166.2 ng/mL)。各组间Tumstatin水平无显著差异。结论:骨桥蛋白水平升高与较高的Gleason评分和转移潜力相关,而较低的TSP1和内皮抑素水平与晚期肿瘤进展相关。这些生物标志物可以作为前列腺癌预后的指标,但需要更大规模的研究来验证。
{"title":"Angiogenesis biomarkers in prostate cancer: Unlocking new avenues for prognosis and diagnosis","authors":"Büşra Ecer ,&nbsp;Abdullah Sivrikaya ,&nbsp;Gökhan Ecer ,&nbsp;Serdar Göktaş ,&nbsp;Mehmet Yıldız ,&nbsp;Mehmet Balasar ,&nbsp;Ali Ünlü","doi":"10.1016/j.currproblcancer.2025.101253","DOIUrl":"10.1016/j.currproblcancer.2025.101253","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the levels of angiogenesis-related biomarkers, including Thrombospondin-1 (TSP1), Endostatin, Osteopontin, and Tumstatin, in prostate cancer patients and their relationship with tumor spread and clinical parameters.</div></div><div><h3>Methods</h3><div>This prospective study included 92 participants divided into three groups: 33 prostate cancer patients, 29 patients with benign prostatic hyperplasia (BPH), and 30 healthy controls. Biomarker levels were analyzed and compared among the groups.</div></div><div><h3>Results</h3><div>Osteopontin levels were significantly higher in the prostate cancer group (108.5 ng/mL) compared to the BPH (66.02 ng/mL) and control groups (56.5 ng/mL). TSP1 levels were lower in prostate cancer group (16.3 ng/mL) than in the BPH (25.3 ng/mL) and control groups (21.5 ng/mL). Similarly, Endostatin levels were reduced in the prostate cancer group (146.3 ng/mL) compared to the BPH (163.3 ng/mL) and control groups (166.2 ng/mL). No significant differences in Tumstatin levels were observed among the groups.</div></div><div><h3>Conclusions</h3><div>Elevated Osteopontin levels correlate with higher Gleason scores and metastatic potential, while lower TSP1 and Endostatin levels are associated with advanced tumor progression. These biomarkers may serve as indicators of prognosis in prostate cancer, though larger studies are required for validation.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"59 ","pages":"Article 101253"},"PeriodicalIF":2.3,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRI-fusion biopsy era: the role of perineural invasion in low-risk prostate cancer mri融合活检时代:神经周围浸润在低危前列腺癌中的作用
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2025-09-13 DOI: 10.1016/j.currproblcancer.2025.101251
Nethusan Sivanesan , Gabriela M. Diaz , Sebastien Strachan , Keervani Kandala , Xiwen Zhao , Wei Shen Tan , Michael S. Leapman , Preston C. Sprenkle

Objective

To evaluate whether perineural invasion independently predicts Gleason score upgrading during active surveillance in patients undergoing MRI-US fusion biopsy.

Patients and Methods

We retrospectively analyzed 325 patients initially diagnosed with Gleason Grade Group (GGG) 1 prostate cancer who underwent at least one subsequent biopsy. Demographics, imaging, and clinical variables were recorded. Univariate and multivariate logistic regression models assessed the association between perineural invasion and Gleason upgrading (GGG2+) on follow-up biopsy.

Results

Among 325 eligible patients diagnosed with GGG 1 prostate cancer on initial biopsy, 51 (15%) had perineural invasion, while 274 (84%) did not. Gleason upgrade occurred in 110 (34%) patients. Upgrading was observed in 24 of 51 patients (47%) with perineural invasion, compared to 86 of 274 patients (32%) without perineural invasion (p = 0.03). On univariate analysis, older age (OR 1.03; p=0.03), African American race (OR 2.22; p=0.04), number of positive cores (OR 1.13; p=0.007), and cancer detected on targeted biopsy (OR 2.26; p=0.01) were associated with upgrading. In multivariable analysis, perineural invasion (OR 1.84; p=0.1) was not independently associated with Gleason upgrading when adjusting for PI-RADS 4-5 (OR 1.98; p=0.01). However, cancer detected on targeted biopsy (OR 2.26; p = 0.01) and African American race (OR 3.2; p = 0.01) remained independently associated with upgrading.

Conclusions

In this contemporary series of patients managed with active surveillance in the era of MRI-ultrasound fusion biopsy, perineural invasion is not associated with Gleason upgrade on subsequent biopsy when adjusting for MRI- US fusion biopsy characteristics. Our findings highlight that a PI-RADS 4 or 5 lesion, and cancer found within an MRI-visible lesion are more predictive of subsequent progression in patients with GGG1 PCa.
目的评估在MRI-US融合活检患者主动监测期间,神经周围浸润是否能独立预测Gleason评分升高。患者和方法我们回顾性分析了325例最初诊断为Gleason Grade Group (GGG) 1型前列腺癌的患者,这些患者随后至少进行了一次活检。记录人口统计学、影像学和临床变量。单因素和多因素logistic回归模型评估了神经周围浸润与随访活检Gleason升级(GGG2+)之间的关系。结果在325例符合条件的初始活检诊断为ggg1前列腺癌的患者中,51例(15%)有神经周围浸润,274例(84%)没有。110例(34%)患者出现Gleason升级。51例有周围神经侵犯的患者中有24例(47%)出现升级,而274例无周围神经侵犯的患者中有86例(32%)出现升级(p = 0.03)。在单因素分析中,年龄较大(OR 1.03; p=0.03)、非裔美国人种族(OR 2.22; p=0.04)、阳性核心数(OR 1.13; p=0.007)和靶向活检中检测到的癌症(OR 2.26; p=0.01)与升级相关。在多变量分析中,当调整PI-RADS 4-5时,神经周围浸润(OR 1.84, p=0.1)与Gleason升级不独立相关(OR 1.98, p=0.01)。然而,靶向活检检测到的癌症(OR 2.26, p = 0.01)和非裔美国人种族(OR 3.2, p = 0.01)仍然与升级独立相关。结论:在MRI-超声融合活检时代积极监测的当代患者中,当调整MRI- US融合活检特征时,周围神经侵犯与随后活检的Gleason升级无关。我们的研究结果强调,PI-RADS 4或5病变以及mri可见病变内发现的癌症更能预测GGG1 PCa患者的后续进展。
{"title":"MRI-fusion biopsy era: the role of perineural invasion in low-risk prostate cancer","authors":"Nethusan Sivanesan ,&nbsp;Gabriela M. Diaz ,&nbsp;Sebastien Strachan ,&nbsp;Keervani Kandala ,&nbsp;Xiwen Zhao ,&nbsp;Wei Shen Tan ,&nbsp;Michael S. Leapman ,&nbsp;Preston C. Sprenkle","doi":"10.1016/j.currproblcancer.2025.101251","DOIUrl":"10.1016/j.currproblcancer.2025.101251","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate whether perineural invasion independently predicts Gleason score upgrading during active surveillance in patients undergoing MRI-US fusion biopsy.</div></div><div><h3>Patients and Methods</h3><div>We retrospectively analyzed 325 patients initially diagnosed with Gleason Grade Group (GGG) 1 prostate cancer who underwent at least one subsequent biopsy. Demographics, imaging, and clinical variables were recorded. Univariate and multivariate logistic regression models assessed the association between perineural invasion and Gleason upgrading (GGG2+) on follow-up biopsy.</div></div><div><h3>Results</h3><div>Among 325 eligible patients diagnosed with GGG 1 prostate cancer on initial biopsy, 51 (15%) had perineural invasion, while 274 (84%) did not. Gleason upgrade occurred in 110 (34%) patients. Upgrading was observed in 24 of 51 patients (47%) with perineural invasion, compared to 86 of 274 patients (32%) without perineural invasion (p = 0.03). On univariate analysis, older age (OR 1.03; p=0.03), African American race (OR 2.22; p=0.04), number of positive cores (OR 1.13; p=0.007), and cancer detected on targeted biopsy (OR 2.26; p=0.01) were associated with upgrading. In multivariable analysis, perineural invasion (OR 1.84; p=0.1) was not independently associated with Gleason upgrading when adjusting for PI-RADS 4-5 (OR 1.98; p=0.01). However, cancer detected on targeted biopsy (OR 2.26; p = 0.01) and African American race (OR 3.2; p = 0.01) remained independently associated with upgrading.</div></div><div><h3>Conclusions</h3><div>In this contemporary series of patients managed with active surveillance in the era of MRI-ultrasound fusion biopsy, perineural invasion is not associated with Gleason upgrade on subsequent biopsy when adjusting for MRI- US fusion biopsy characteristics. Our findings highlight that a PI-RADS 4 or 5 lesion, and cancer found within an MRI-visible lesion are more predictive of subsequent progression in patients with GGG1 PCa.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"59 ","pages":"Article 101251"},"PeriodicalIF":2.3,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current perspectives on Lifileucel tumor-infiltrating lymphocyte therapy: A paradigm shift in immunotherapy Lifileucel肿瘤浸润性淋巴细胞治疗的现状:免疫治疗的范式转变
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2025-09-12 DOI: 10.1016/j.currproblcancer.2025.101252
Simran Deep Kaur , Md Abubakar , Neena Bedi , Eswara Rao puppala , Deepak N Kapoor , Nitesh Kumar , Nafees Ahemad , Sirajudheen Anwar
Lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, provides renewed hope for individuals with advanced, treatment-resistant malignancies. This is a groundbreaking advancement in cancer immunotherapy. Revolutionizing the way the immune system fights cancer, this state-of-the-art cellular therapy takes advantage of TILs' innate capacity to target tumors. Lifileucel is an innovative medicine that is garnering attention in oncology. It has shown remarkable efficacy in clinical trials, assisting individuals unresponsive to other therapy in sustaining their responses and enhancing their survival rates. This paper provides a comprehensive overview of contemporary perspectives on Lifileucel, including its mechanism of action, clinical results, challenges and potential applicability to a broader spectrum of solid tumors. The Lifileucel concept has initiated a new epoch in personalized cancer therapy. This review offers a forward-looking perspective on the potential advancements and opportunities for establishing Lifileucel and TIL-based therapies as a cornerstone in cancer therapy.
Lifileucel是一种肿瘤浸润性淋巴细胞(TIL)疗法,为晚期恶性肿瘤患者提供了新的希望。这是癌症免疫疗法的突破性进展。这种最先进的细胞疗法利用了TILs靶向肿瘤的先天能力,彻底改变了免疫系统对抗癌症的方式。Lifileucel是在肿瘤学领域备受关注的创新药物。它在临床试验中显示出显著的疗效,帮助对其他治疗无反应的个体维持其反应并提高其生存率。本文全面概述了Lifileucel的当代观点,包括其作用机制、临床结果、挑战和在更广泛的实体肿瘤中的潜在适用性。Lifileucel的概念开启了个体化癌症治疗的新纪元。这篇综述为建立Lifileucel和基于til的治疗作为癌症治疗基石的潜在进展和机会提供了前瞻性的观点。
{"title":"Current perspectives on Lifileucel tumor-infiltrating lymphocyte therapy: A paradigm shift in immunotherapy","authors":"Simran Deep Kaur ,&nbsp;Md Abubakar ,&nbsp;Neena Bedi ,&nbsp;Eswara Rao puppala ,&nbsp;Deepak N Kapoor ,&nbsp;Nitesh Kumar ,&nbsp;Nafees Ahemad ,&nbsp;Sirajudheen Anwar","doi":"10.1016/j.currproblcancer.2025.101252","DOIUrl":"10.1016/j.currproblcancer.2025.101252","url":null,"abstract":"<div><div>Lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, provides renewed hope for individuals with advanced, treatment-resistant malignancies. This is a groundbreaking advancement in cancer immunotherapy. Revolutionizing the way the immune system fights cancer, this state-of-the-art cellular therapy takes advantage of TILs' innate capacity to target tumors. Lifileucel is an innovative medicine that is garnering attention in oncology. It has shown remarkable efficacy in clinical trials, assisting individuals unresponsive to other therapy in sustaining their responses and enhancing their survival rates. This paper provides a comprehensive overview of contemporary perspectives on Lifileucel, including its mechanism of action, clinical results, challenges and potential applicability to a broader spectrum of solid tumors. The Lifileucel concept has initiated a new epoch in personalized cancer therapy. This review offers a forward-looking perspective on the potential advancements and opportunities for establishing Lifileucel and TIL-based therapies as a cornerstone in cancer therapy.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"59 ","pages":"Article 101252"},"PeriodicalIF":2.3,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A phase 2 prospective trial of re-irradiation of locally recurrent or second primary head and neck tumors using stereotactic body radiation therapy 一项使用立体定向全身放射治疗局部复发或第二原发头颈部肿瘤再照射的2期前瞻性试验
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2025-09-11 DOI: 10.1016/j.currproblcancer.2025.101241
Sally Fouda , Tarek Hamed Shouman , Ashraf Hamed Hassouna , Ayman Abdelwahab Amin , Maha Hassan , Shaimaa Abdelgeleel , May Gamal Ashour

Objective

To assess SBRT in the reirradiation of head and neck (H&N) cancers.

Patients and Methods

30 patients with 31 sites received SBRT reirradiation to their recurrences, or second primary malignancies (SPM). Doses used were 30-50 Gy in 5 fractions. SBRT reirradiation was used alone for 21 recurrences, while 10 patients received SBRT postoperatively. Assessment of toxicity after reirradiation was done using RTOG scoring criteria.

Results

Median follow up was 18.2 months. In patients treated with RT alone (N = 21), at 3 months post reirradiation, CR (complete response) was achieved in 13 patients (61.9 %). CR rate increased to include 16 patients (76.2 %) at 6 months. In patients treated with adjuvant SBRT (N = 10), at 3 months post reirradiation, no recurrences were observed in 6 patients (60 %).
Median survival was 29.8 months. The 1-year and 2-year OS were 66.2 % and 54.2 % respectively. The 1-year and 2-year PFS were 45.8 % and 32.1 % respectively. The 1-year and 2-year LC were 62.7 % and 54.8 % respectively. The 1-year and 2-year regional control were 79.7 % and 73.6 % respectively. The 1-year and 2-year distant control were 88.4 % and 82.9 % respectively. Acute toxicity of ≥ G3 happened in 5 patients (16.1 %). Late toxicity of ≥ G3 was recorded in 9 patients (29 %).

Conclusion

We reported the 1st prospective phase 2 study in Egypt to use SBRT reirradiation for recurrent H&N cancers. SBRT reirradiation can be a good option for treatment, with good survival and control rates, and acceptable toxicity.
目的评价SBRT在头颈部(H&;N)肿瘤再照射中的作用。患者和方法30例31个部位的患者对其复发或第二原发恶性肿瘤(SPM)进行SBRT再照射。剂量为30-50 Gy,分5次使用。21例复发患者单独使用SBRT再放疗,10例术后接受SBRT治疗。再照射后毒性评价采用RTOG评分标准。结果中位随访时间为18.2个月。在单独接受放射治疗的患者中(N = 21),在再照射后3个月,13例患者(61.9%)达到了CR(完全缓解)。6个月时,16例患者(76.2%)的CR率上升。在接受辅助SBRT治疗的患者中(N = 10),在再照射后3个月,6例患者(60%)未观察到复发。中位生存期为29.8个月。1年OS为66.2%,2年OS为54.2%。1年和2年PFS分别为45.8%和32.1%。1年和2年的LC分别为62.7%和54.8%。1年和2年区域控制率分别为79.7%和73.6%。1年和2年远期控制率分别为88.4%和82.9%。急性毒性≥G3者5例(16.1%)。9例(29%)出现≥G3的晚期毒性。结论:我们报道了在埃及进行的第一个前瞻性2期研究,该研究使用SBRT再照射治疗复发性H&;N癌。SBRT再照射是一种良好的治疗选择,具有良好的生存率和控制率,毒性可接受。
{"title":"A phase 2 prospective trial of re-irradiation of locally recurrent or second primary head and neck tumors using stereotactic body radiation therapy","authors":"Sally Fouda ,&nbsp;Tarek Hamed Shouman ,&nbsp;Ashraf Hamed Hassouna ,&nbsp;Ayman Abdelwahab Amin ,&nbsp;Maha Hassan ,&nbsp;Shaimaa Abdelgeleel ,&nbsp;May Gamal Ashour","doi":"10.1016/j.currproblcancer.2025.101241","DOIUrl":"10.1016/j.currproblcancer.2025.101241","url":null,"abstract":"<div><h3>Objective</h3><div>To assess SBRT in the reirradiation of head and neck (H&amp;N) cancers.</div></div><div><h3>Patients and Methods</h3><div>30 patients with 31 sites received SBRT reirradiation to their recurrences, or second primary malignancies (SPM). Doses used were 30-50 Gy in 5 fractions. SBRT reirradiation was used alone for 21 recurrences, while 10 patients received SBRT postoperatively. Assessment of toxicity after reirradiation was done using RTOG scoring criteria.</div></div><div><h3>Results</h3><div>Median follow up was 18.2 months. In patients treated with RT alone (<em>N</em> = 21), at 3 months post reirradiation, CR (complete response) was achieved in 13 patients (61.9 %). CR rate increased to include 16 patients (76.2 %) at 6 months. In patients treated with adjuvant SBRT (<em>N</em> = 10), at 3 months post reirradiation, no recurrences were observed in 6 patients (60 %).</div><div>Median survival was 29.8 months. The 1-year and 2-year OS were 66.2 % and 54.2 % respectively. The 1-year and 2-year PFS were 45.8 % and 32.1 % respectively. The 1-year and 2-year LC were 62.7 % and 54.8 % respectively. The 1-year and 2-year regional control were 79.7 % and 73.6 % respectively. The 1-year and 2-year distant control were 88.4 % and 82.9 % respectively. Acute toxicity of ≥ G3 happened in 5 patients (16.1 %). Late toxicity of ≥ G3 was recorded in 9 patients (29 %).</div></div><div><h3>Conclusion</h3><div>We reported the 1st prospective phase 2 study in Egypt to use SBRT reirradiation for recurrent H&amp;N cancers. SBRT reirradiation can be a good option for treatment, with good survival and control rates, and acceptable toxicity.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"59 ","pages":"Article 101241"},"PeriodicalIF":2.3,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Title Page 标题页
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2025-09-09 DOI: 10.1016/S0147-0272(25)00071-6
{"title":"Title Page","authors":"","doi":"10.1016/S0147-0272(25)00071-6","DOIUrl":"10.1016/S0147-0272(25)00071-6","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"58 ","pages":"Article 101244"},"PeriodicalIF":2.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145018638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Information for Readers 读者资讯
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2025-09-09 DOI: 10.1016/S0147-0272(25)00072-8
{"title":"Information for Readers","authors":"","doi":"10.1016/S0147-0272(25)00072-8","DOIUrl":"10.1016/S0147-0272(25)00072-8","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"58 ","pages":"Article 101245"},"PeriodicalIF":2.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145018458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics and treatment analysis of pulmonary blastoma (PB): a report of 17 cases 肺母细胞瘤(PB) 17例临床特点及治疗分析
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2025-08-22 DOI: 10.1016/j.currproblcancer.2025.101240
Jiaqi Guan , Jinglai Sun , Zhiping Hu , Yuhan liu , Jiwei Ma , Jinghong Wang , Bangzhen Ma

Introduction

To summarize the disease characteristics of pulmonary blastoma, analyze related prognostic factors, and share the diagnosis and treatment process.

Methods

This study retrospectively analyzed the clinical data of 17 patients with pulmonary blastoma admitted to Shandong Provincial Hospital from January 1994 to December 2024.

Results

The patients were predominantly middle-aged and elderly males, with clinical manifestations mainly including cough, sputum production, chest tightness, and shortness of breath. Chest CT combined with elevated serum neuron-specific enolase (NSE) may assist in diagnosis. The pathological types were predominantly biphasic, followed by epithelial type and those with unclear subtypes. Tumors were more likely to occur in the right lung, and most were at T4 stage or accompanied by regional lymph node metastasis at the time of diagnosis. The higher the Ki-67 positive cell viability rate, the shorter the survival time. Lobectomy is currently an effective treatment, and postoperative radiotherapy can improve the survival time of some patients. The 5-year survival rate was 29.4%. Cox regression analysis showed that gender and tumor stage T had statistical significance for the prognosis of patients with pulmonary blastoma. Verification via Kaplan-Meier survival curves revealed that the survival time of patients with T4 stage was significantly shorter than that of patients with early-stage disease (Log-rank p=0.011).

Conclusions

Preoperative diagnosis of pulmonary blastoma is challenging, with the biphasic type being the predominant pathological subtype. The advanced stage at the time of diagnosis is a key factor for poor prognosis. There is a significant difference in age between pediatric and adult patients. Tumor stage is a key factor affecting prognosis, and the Ki-67 positivity rate is negatively correlated with survival time. Emphasizing the formulation of treatment strategies based on pathological types and tumor stages can provide a reference for improving the level of diagnosis and treatment.
前言总结肺母细胞瘤的疾病特点,分析相关预后因素,分享诊断和治疗过程。方法回顾性分析1994年1月至2024年12月山东省立医院收治的17例肺母细胞瘤患者的临床资料。结果患者以中老年男性为主,临床表现以咳嗽、咳痰、胸闷、气短为主。胸部CT结合血清神经元特异性烯醇化酶(NSE)升高可能有助于诊断。病理类型以双相型为主,其次为上皮型,亚型不明确。肿瘤多发于右肺,诊断时多为T4期或伴有局部淋巴结转移。Ki-67阳性细胞存活率越高,存活时间越短。目前肺叶切除术是一种有效的治疗方法,术后放疗可提高部分患者的生存时间。5年生存率为29.4%。Cox回归分析显示,性别和肿瘤分期对肺母细胞瘤患者的预后有统计学意义。Kaplan-Meier生存曲线验证显示,T4期患者的生存时间明显短于早期患者(Log-rank p=0.011)。结论肺母细胞瘤的术前诊断具有挑战性,以双相型为主要病理亚型。诊断时的晚期是导致预后不良的关键因素。儿童和成人患者在年龄上有显著差异。肿瘤分期是影响预后的关键因素,Ki-67阳性率与生存时间呈负相关。强调根据病理分型和肿瘤分期制定治疗策略,可为提高诊治水平提供参考。
{"title":"Clinical characteristics and treatment analysis of pulmonary blastoma (PB): a report of 17 cases","authors":"Jiaqi Guan ,&nbsp;Jinglai Sun ,&nbsp;Zhiping Hu ,&nbsp;Yuhan liu ,&nbsp;Jiwei Ma ,&nbsp;Jinghong Wang ,&nbsp;Bangzhen Ma","doi":"10.1016/j.currproblcancer.2025.101240","DOIUrl":"10.1016/j.currproblcancer.2025.101240","url":null,"abstract":"<div><h3>Introduction</h3><div>To summarize the disease characteristics of pulmonary blastoma, analyze related prognostic factors, and share the diagnosis and treatment process.</div></div><div><h3>Methods</h3><div>This study retrospectively analyzed the clinical data of 17 patients with pulmonary blastoma admitted to Shandong Provincial Hospital from January 1994 to December 2024.</div></div><div><h3>Results</h3><div>The patients were predominantly middle-aged and elderly males, with clinical manifestations mainly including cough, sputum production, chest tightness, and shortness of breath. Chest CT combined with elevated serum neuron-specific enolase (NSE) may assist in diagnosis. The pathological types were predominantly biphasic, followed by epithelial type and those with unclear subtypes. Tumors were more likely to occur in the right lung, and most were at T4 stage or accompanied by regional lymph node metastasis at the time of diagnosis. The higher the Ki-67 positive cell viability rate, the shorter the survival time. Lobectomy is currently an effective treatment, and postoperative radiotherapy can improve the survival time of some patients. The 5-year survival rate was 29.4%. Cox regression analysis showed that gender and tumor stage T had statistical significance for the prognosis of patients with pulmonary blastoma. Verification via Kaplan-Meier survival curves revealed that the survival time of patients with T4 stage was significantly shorter than that of patients with early-stage disease (Log-rank <em>p</em>=0.011).</div></div><div><h3>Conclusions</h3><div>Preoperative diagnosis of pulmonary blastoma is challenging, with the biphasic type being the predominant pathological subtype. The advanced stage at the time of diagnosis is a key factor for poor prognosis. There is a significant difference in age between pediatric and adult patients. Tumor stage is a key factor affecting prognosis, and the Ki-67 positivity rate is negatively correlated with survival time. Emphasizing the formulation of treatment strategies based on pathological types and tumor stages can provide a reference for improving the level of diagnosis and treatment.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"58 ","pages":"Article 101240"},"PeriodicalIF":2.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144885817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of toripalimab in treating nasopharyngeal carcinoma: A meta-analysis 托帕利单抗治疗鼻咽癌的疗效和安全性:一项荟萃分析
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2025-07-31 DOI: 10.1016/j.currproblcancer.2025.101238
Yiwei Sun , Lingqin Kong

Purpose

To systematically assess the effectiveness and safety of toripalimab in the treatment of nasopharyngeal carcinoma (NPC) based on clinical trial reports.

Methods

Four databases (PubMed, Web of Science, Embase, and The Cochrane Library) were comprehensively searched to collect randomized controlled trials (RCTs) or single-arm clinical trials of toripalimab in treating NPC up to May 8, 2025. Two investigators independently screened relevant studies according to the inclusion/exclusion criteria. Data analyses were performed using R4.0 software.

Results

This analysis included 9 trials, including 7 single-arm trials and 2 RCTs, involving a total of 608 patients. The meta-analysis results indicated that toripalimab could improve objective response rate (RR=0.780, 95 % CI: 0.554-0.911) and disease control rate (RR = 0.921, 95 % CI: 0.788-0.992) in NPC patients. Nonetheless, toripalimab administration could also induce adverse reactions. The incidence of the following adverse reactions was relatively high, at 60.6 % for anemia, 65.4 % for nausea, and 46.1 % for leukopenia.

Conclusion

Toripalimab administration can significantly improve the objective response rate and disease control rate in NPC patients. Meanwhile, specific clinical measures shall be taken to prevent and manage the adverse reactions induced by this medication.
目的根据临床试验报告,系统评价托帕利单抗治疗鼻咽癌的有效性和安全性。方法综合检索PubMed、Web of Science、Embase、The Cochrane Library 4个数据库,收集截至2025年5月8日的托帕利单抗治疗鼻咽癌的随机对照试验(RCTs)或单臂临床试验。两名研究者根据纳入/排除标准独立筛选相关研究。采用R4.0软件进行数据分析。结果本分析纳入9项试验,包括7项单臂试验和2项随机对照试验,共涉及608例患者。meta分析结果显示,托帕利单抗可提高鼻咽癌患者的客观有效率(RR=0.780, 95% CI: 0.554-0.911)和疾病控制率(RR= 0.921, 95% CI: 0.788-0.992)。然而,托帕利单抗也可能引起不良反应。以下不良反应的发生率相对较高,贫血为60.6%,恶心为65.4%,白细胞减少为46.1%。结论托利帕单抗可显著提高鼻咽癌患者的客观有效率和疾病控制率。同时,应采取针对性的临床措施,预防和管理本品引起的不良反应。
{"title":"Efficacy and safety of toripalimab in treating nasopharyngeal carcinoma: A meta-analysis","authors":"Yiwei Sun ,&nbsp;Lingqin Kong","doi":"10.1016/j.currproblcancer.2025.101238","DOIUrl":"10.1016/j.currproblcancer.2025.101238","url":null,"abstract":"<div><h3>Purpose</h3><div>To systematically assess the effectiveness and safety of toripalimab in the treatment of nasopharyngeal carcinoma (NPC) based on clinical trial reports.</div></div><div><h3>Methods</h3><div>Four databases (PubMed, Web of Science, Embase, and The Cochrane Library) were comprehensively searched to collect randomized controlled trials (RCTs) or single-arm clinical trials of toripalimab in treating NPC up to May 8, 2025. Two investigators independently screened relevant studies according to the inclusion/exclusion criteria. Data analyses were performed using R4.0 software.</div></div><div><h3>Results</h3><div>This analysis included 9 trials, including 7 single-arm trials and 2 RCTs, involving a total of 608 patients. The meta-analysis results indicated that toripalimab could improve objective response rate (RR=0.780, 95 % CI: 0.554-0.911) and disease control rate (RR = 0.921, 95 % CI: 0.788-0.992) in NPC patients. Nonetheless, toripalimab administration could also induce adverse reactions. The incidence of the following adverse reactions was relatively high, at 60.6 % for anemia, 65.4 % for nausea, and 46.1 % for leukopenia.</div></div><div><h3>Conclusion</h3><div>Toripalimab administration can significantly improve the objective response rate and disease control rate in NPC patients. Meanwhile, specific clinical measures shall be taken to prevent and manage the adverse reactions induced by this medication.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"58 ","pages":"Article 101238"},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Problems in Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1